Board of Directors

James L. Tyree
President, Abbott Biotech Ventures Inc.

James L. Tyree is president, Abbott Biotech Ventures Inc. and is responsible for the company's biotechnology business development projects. Previously, Tyree was executive vice president, Pharmaceutical Products Group, where he was responsible for Abbott's global pharmaceutical business, including commercial operations, research and development, and manufacturing. He was appointed to his current role in August 2009.

Tyree has served in various management positions including was senior vice president for Abbott's U.S. pharmaceutical business and senior vice president for Abbott's global nutrition business. He also served as vice president, global pharmaceutical licensing/new business development, and as divisional vice president and general manager for Abbott's international pharmaceutical business in Japan.

Previously, Tyree was president of Sugen Inc., a biotechnology start-up company and held various leadership positions at other pharmaceutical companies. He originally joined Abbott in a finance position upon his college graduation.

He is a member of the advisory boards of the University of Chicago Council on Chicago Booth and the University of Chicago ADVANCE. He is a member of the advisory board of the Kellogg Center for Biotechnology at Northwestern University. He is a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. He is past chairman and current member of the executive committee of the board of directors of the Illinois Biotechnology Industry Organization. He is an executive committee member of the 2010 BIO International Convention. He is also a member of the Economic Club of Chicago.

Tyree earned a bachelor's degree in psychology and forensic studies, and a master's degree in business administration from Indiana University.

Back


65 East Wacker Place Suite 1600, Chicago, IL 60601 P: 312.422.1111 F: 312.422.1145
The Institute is a not-for-profit corporation and is tax-exempt as a public charity under Sections 501(c)(3) and 509 of the Internal Revenue Code.